MC
VCNX

Moors & Cabot’s Vaccinex, Inc. Common Stock VCNX Stock Holding History

Moors & Cabot’s Portfolio VCNX Stock Details VCNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-48
Closed -$3.56K – 887
2023
Q2 		$3.56K Hold
48
– – ﹤0.01% 832
2023
Q1 		$4K Hold
48
– – ﹤0.01% 854
2022
Q4 		$6.45K Hold
48
– – ﹤0.01% 833
2022
Q3 		$5K Hold
48
– – ﹤0.01% 810
2022
Q2 		$11K Hold
48
– – ﹤0.01% 793
2022
Q1 		$13K Buy
+48
New +$13.3K ﹤0.01% 856

Other funds holding VCNX

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TC
Tacita Capital Toronto, Ontario, Canada $184M AUM 26.11% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Moors & Cabot's VCNX Position: Q3 2023 in Review

Moors & Cabot sold out of Vaccinex, Inc. Common Stock (VCNX) in Q3 2023, closing a stake of 48 shares — an estimated $3.56K sold.

Moors & Cabot first reported a position in VCNX in Q1 2022 and held it in 6 quarters. The position peaked at $13K in Q1 2022. 18 funds tracked by Wall St. Rank hold VCNX as of Q3 2023.

  • Moors & Cabot reported no remaining Vaccinex, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Moors & Cabot sold 48 Vaccinex, Inc. Common Stock shares in Q3 2023, an estimated $3.56K.
  • Moors & Cabot first reported a position in Vaccinex, Inc. Common Stock in Q1 2022 and held it in 6 quarters.
  • Moors & Cabot's Vaccinex, Inc. Common Stock position peaked at $13K in Q1 2022.
  • 18 funds tracked by Wall St. Rank held Vaccinex, Inc. Common Stock as of Q3 2023.

Based on Moors & Cabot's 13F filing for Q3 2023, filed 8 Nov 2023.